Medical News

RSS

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lennart Mucke, MD, Director of the Gladstone Institute of Neurological Disease (GIND), has been named a recipient of the American Academy of Neurology's prestigious Potamkin Prize.

19 Feb 2010

IMS Health launches IMS Aggregate Spend Compliance Services

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the launch of IMS Aggregate Spend Compliance Services, a comprehensive set of solutions to help pharmaceutical and medical device companies comply with the growing number of federal and state transparency and marketing disclosure laws in the U.S., known as “aggregate spend” reporting regulations.

18 Feb 2010

GOP, Democrats staking out reform positions, strategies in advance of health summit

The Associated Press: The White House is preparing a bill "designed to win passage without Republican support if GOP lawmakers fail to embrace bipartisan compromises" during next weeek's White House health summit.

18 Feb 2010

Lower dose of avosentan drug may provide more favorable results in diabetes patients

The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious side effects, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

18 Feb 2010

Michigan sends letters to 500,000 warning COBRA expiration

Michigan's state unemployment insurance agency has sent letters to 500,000 residents warning them that their benefits could expire starting in March if Congress fails to act on extending jobless benefits including a federal subsidy for COBRA health insurance, The Detroit News reports.

18 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

AMICAS postpones Special Meeting of Stockholders to vote on pending merger agreement

AMICAS, Inc., a leader in image and information management solutions, today announced that it will convene and adjourn its Special Meeting of Stockholders to consider and vote on the pending merger agreement with an affiliate of Thoma Bravo, LLC.

18 Feb 2010

Dartmouth Atlas analyses of hospital spending called 'flawed'

The New York Times reports that certain hospitals, including the Mayo Clinic, are lauded "for delivering high-quality care at low costs" based on "a widely cited analysis called the Dartmouth Atlas of Health Care."

18 Feb 2010

Obama admin. to redouble campaign against insurers' rate hikes

After criticizing California insurer Anthem for raising premiums 10 days ago, Obama administration officials are preparing for more, The Washington Post reports. "Health and Human Services Secretary Kathleen Sebelius has scheduled a late-morning news conference, at which she is to cite half a dozen examples," where insurers have sought big rate hikes for individual coverage.

18 Feb 2010

NXT Nutritionals Holdings secures $2.35M financing

NXT Nutritionals Holdings, Inc., developer and marketer of SUSTA™ Natural Sweetener, the great tasting, all-natural, healthier sweetener, announced today that the Company has secured $2.35 million in financing through a private placement offering (the “Offering”). Proceeds from the Offering will be used for general corporate purposes and to fund further development and marketing of its SUSTA™ products.

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows.

18 Feb 2010

A selection of today's opinions and editorials

The epic of health care evolution is complex and is worth reviewing over the last five decades. Having practiced medicine in the same community in Southeast Missouri for more than 30 years, I have seen changes in health care beyond the scope of imagination (Dr. S.D. Madduri, 2/18).

18 Feb 2010

Humana schedules layoffs as insurers struggle to cut costs

Dow Jones Newswires/Wall Street Journal reports that Humana, one of the nation's largest health insurers, "said it will shed nearly 1,400 jobs, or 5% of its work force, this year" because of declines in enrollment. The company will cut a total of 2,500 jobs, but plans to hire 1,100 new employees to help with such issues as controlling medical costs and managing pharmacy benefits.

18 Feb 2010

Gen-Probe board authorizes $100M stock repurchase plan

Gen-Probe Incorporated announced today that its board of directors has authorized the repurchase of up to $100 million of the Company's common stock over the next year.

18 Feb 2010

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

Epeius Biotechnologies (www.epeiusbiotech.com) announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in GMP, CMC, aseptic processing, and quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century.

18 Feb 2010

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

One in eight women diagnosed with breast cancer is younger than 45 when diagnosed, yet their emotional and medical concerns are different than those of women over age 45, as is the impact of their diagnosis on family, friends, partners, colleagues and children.

18 Feb 2010

States' retiree benefits underfunded by at least $1 trillion

State governments' retiree pension and health plans are severely underfunded, according to a new report from the Pew Center on States.

18 Feb 2010

Medical News

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

IMS Health launches IMS Aggregate Spend Compliance Services

GOP, Democrats staking out reform positions, strategies in advance of health summit

Lower dose of avosentan drug may provide more favorable results in diabetes patients

Michigan sends letters to 500,000 warning COBRA expiration

FDA approves Rituxan-FC combination therapy for CLL

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

AMICAS postpones Special Meeting of Stockholders to vote on pending merger agreement

Dartmouth Atlas analyses of hospital spending called 'flawed'

Obama admin. to redouble campaign against insurers' rate hikes

NXT Nutritionals Holdings secures $2.35M financing

Rituxan, intended for patients with CLL receives FDA approval

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

A selection of today's opinions and editorials

Humana schedules layoffs as insurers struggle to cut costs

Gen-Probe board authorizes $100M stock repurchase plan

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

States' retiree benefits underfunded by at least $1 trillion

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News